{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:33:58Z","timestamp":1745469238141,"version":"3.40.4"},"reference-count":29,"publisher":"S. Karger AG","issue":"1-2","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology"],"published-print":{"date-parts":[[2014]]},"abstract":"<jats:p>This study was designed to investigate the efficacy of a partial \u03bc-opioid agonist, buprenorphine, against the formalin-induced hyperalgesia in the upper lip in chronically inferior alveolar nerve (IAN)-transected rats. Subcutaneous injection of diluted formalin into the upper lip in the IAN-transected rats showed an increased number of pain-related behavior (PRB; face-rubbing behavior) in every phase up to 45 min (p &lt; 0.01) compared with that in the nontransected sham control rats. The numbers of c-Fos-immunoreactive (IR) cells in the superficial layers of the trigeminal nucleus caudalis (VcI\/II) at the rostral (0-0.7 mm caudal to the obex) and middle levels (1.4-2.2 mm caudal to the obex) 2 h after the formalin injection in the IAN-transected rats were significantly increased compared with those in the control rats. The PRB in phases 1 and 2 (0-15 and 15-30 min after formalin injection) in rats with preadministration of morphine (3 mg\/kg i.p.) or buprenorphine (100 \u00b5g\/kg i.p.) was significantly (p &lt; 0.05) smaller than those in the control rats. There was no significant difference in the efficacy between morphine and buprenorphine at these doses. The antinociceptive efficacy in phase 2 of buprenorphine (100 \u00b5g\/kg) was higher (p &lt; 0.05) than that of morphine (3 mg\/kg) in the IAN-transected rats. The number of c-Fos-IR cells in the VcI\/II at every level (0-3.6 mm caudal to the obex) after formalin injection was significantly decreased (p &lt; 0.01) with preadministration of morphine (3 mg\/kg) or buprenorphine (100 \u00b5g\/kg) in the control rats. In the IAN-transected rats, the number of c-Fos-IR cells in the caudal VcI\/II (2.2-3.6 mm caudal to the obex) after formalin injection was significantly decreased (p &lt; 0.01) with preadministration of buprenorphine (100 \u00b5g\/kg) but not so much (2.2-2.9 mm caudal to the obex, p &lt; 0.05; 2.9-3.6 mm caudal to the obex, p &gt; 0.05) with preadministration of morphine (3 mg\/kg). These results indicate that IAN transection enhanced formalin-induced nocifensive responses in the upper lip, the dermatome of the intact nerve neighboring the IAN. Systemic preadministration of buprenorphine had more antinociceptive effects on the formalin-induced nocifensive behavior in the upper lip compared with morphine in the IAN-transected rats.<\/jats:p>","DOI":"10.1159\/000356713","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T07:17:15Z","timestamp":1389165435000},"page":"10-17","source":"Crossref","is-referenced-by-count":3,"title":["Inferior Alveolar Nerve Transection Enhanced Formalin-Induced Nocifensive Responses in the Upper Lip: Systemic Buprenorphine Had More Antinociceptive Efficacy over Morphine"],"prefix":"10.1159","volume":"93","author":[{"given":"Fumiko","family":"Kuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Sugiyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Niwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohide","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2014,1,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)01307-0"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(03)03529-7"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(01)00403-1"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.07.014"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(95)12026-Z"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(98)00146-8"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-9781(00)00252-7"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/j.sane.2003.12.012"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(94)00273-H"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2004.06.019"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.12.030"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2006.04.010"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00221-009-1842-1"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)02052-6"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-60777-6_10"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2005.05.046"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3388-05.2006"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(00)80966-6"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/cne.902030414"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.1989.tb02897.x"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(97)03329-0"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(97)13401-2"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.046979"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(01)00459-6"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)01833-2"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(97)00240-6"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.13029SC"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.100859"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2007.01.001"}],"container-title":["Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/356713","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/356713","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:21:16Z","timestamp":1745432476000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000356713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":29,"journal-issue":{"issue":"1-2","published-online":{"date-parts":[[2014,3,1]]},"published-print":{"date-parts":[[2014,3,6]]}},"URL":"https:\/\/doi.org\/10.1159\/000356713","archive":["Portico"],"relation":{},"ISSN":["0031-7012","1423-0313"],"issn-type":[{"type":"print","value":"0031-7012"},{"type":"electronic","value":"1423-0313"}],"subject":[],"published":{"date-parts":[[2014]]}}}